Literature DB >> 16913845

Transcription factor FOXM1c is repressed by RB and activated by cyclin D1/Cdk4.

Inken Wierstra1, Jürgen Alves.   

Abstract

The proliferation-stimulating transactivator FOXM1c (MPP2) is repressed by RB and activated by cyclin D1/Cdk4 and therefore behaves like E2F. Despite its strong transactivation domain, FOXM1c is kept almost inactive by two different inhibitory domains, the N-terminus and the central domain. The tumor suppressor RB binds directly to the central domain of FOXM1c and thereby indirectly represses the transactivation domain, so that the central domain of FOXM1c functions as an RB-recruiting negative-regulatory domain. Cyclin D1/Cdk4 releases FOXM1c from this repression by RB and from the repression by its own inhibitory N-terminus, thereby strongly activating FOXM1c. However, cyclin D1/Cdk4 does not directly affect the transactivation domain or the DNA-binding domain. By phosphorylation of RB, but not FOXM1c, cyclin D1/Cdk4 interrupts their direct interaction and thus abrogates the repression of FOXM1c by RB. Cyclin D1/Cdk4 also eliminates the inhibition of the transactivation domain by the N-terminus of FOXM1c, probably by interruption of their direct interaction. Consequently, the G1-phase proliferation signal cyclin D1/Cdk4 converts FOXM1c from an almost inactive form into a strong transactivator in G1-phase, i.e., just at the time point at which the transcriptional activity of FOXM1 is required for stimulation of the G1/S-transition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16913845     DOI: 10.1515/BC.2006.119

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  29 in total

1.  Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer.

Authors:  Chellappagounder Thangavel; Ettickan Boopathi; Yi Liu; Christopher McNair; Alex Haber; Maryna Perepelyuk; Anshul Bhardwaj; Sankar Addya; Adam Ertel; Sunday Shoyele; Ruth Birbe; Joseph M Salvino; Adam P Dicker; Karen E Knudsen; Robert B Den
Journal:  Clin Cancer Res       Date:  2018-01-08       Impact factor: 12.531

2.  An N-terminal inhibitory domain modulates activity of FoxM1 during cell cycle.

Authors:  H J Park; Z Wang; R H Costa; A Tyner; L F Lau; P Raychaudhuri
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

Review 3.  Targeting forkhead box M1 transcription factor in breast cancer.

Authors:  Ruth M O'Regan; Rita Nahta
Journal:  Biochem Pharmacol       Date:  2018-05-31       Impact factor: 5.858

4.  FoxM1 regulates mammary luminal cell fate.

Authors:  Janai R Carr; Megan M Kiefer; Hyun Jung Park; Jing Li; Zebin Wang; Joel Fontanarosa; Danielle DeWaal; Dragana Kopanja; Elizaveta V Benevolenskaya; Grace Guzman; Pradip Raychaudhuri
Journal:  Cell Rep       Date:  2012-06-07       Impact factor: 9.423

Review 5.  Forkhead box proteins: tuning forks for transcriptional harmony.

Authors:  Eric W-F Lam; Jan J Brosens; Ana R Gomes; Chuay-Yeng Koo
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

Review 6.  Roles of FoxM1 in cell regulation and breast cancer targeting therapy.

Authors:  Xin Song; Samuel Selorm Fiati Kenston; Jinshun Zhao; Danting Yang; Yuanliang Gu
Journal:  Med Oncol       Date:  2017-02-08       Impact factor: 3.064

7.  Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis.

Authors:  T S Karin Eisinger-Mathason; Vera Mucaj; Kevin M Biju; Michael S Nakazawa; Mercy Gohil; Timothy P Cash; Sam S Yoon; Nicolas Skuli; Kyung Min Park; Sharon Gerecht; M Celeste Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-15       Impact factor: 11.205

8.  Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.

Authors:  Julieann Rader; Mike R Russell; Lori S Hart; Michael S Nakazawa; Lili T Belcastro; Daniel Martinez; Yimei Li; Erica L Carpenter; Edward F Attiyeh; Sharon J Diskin; Sunkyu Kim; Sudha Parasuraman; Giordano Caponigro; Robert W Schnepp; Andrew C Wood; Bruce Pawel; Kristina A Cole; John M Maris
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

9.  FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.

Authors:  J Millour; D Constantinidou; A V Stavropoulou; M S C Wilson; S S Myatt; J M-M Kwok; K Sivanandan; R C Coombes; R H Medema; J Hartman; A E Lykkesfeldt; E W-F Lam
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

Review 10.  FOX(M1) news--it is cancer.

Authors:  Marianna Halasi; Andrei L Gartel
Journal:  Mol Cancer Ther       Date:  2013-02-26       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.